I nitial safety and efficacy data from the   single agent RP2 portion of the Phase 1 clinical trial of RP2 alone & in combination with Opdivo® ( nivolumab ) in patients with solid tumors An u pdate from the melanoma & non-melanoma skin cancer   patients enrolled into the Phase 1/2 clinical trial of